Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study
Authors:
- Ian H. de BoerIBIan H. de Boer
- John M. LachinJLJohn M. Lachin
- Trevor OrchardTOTrevor Orchard
- Andrew D. PatersonAPAndrew D. Paterson
- for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research GroupFGfor the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group
Open Access
- 24 October 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 11 (11) , 1969-1977
Abstract
Background and objectives: In trials of people with type 2 diabetes, albuminuria reduction with renin-angiotensin system inhibitors is associated with lower risks of cardiovascular events and CKD progression. We tested whether progression or remission of microalbuminuria is associated with cardiovascular and renal risk in a well characterized cohort of type 1 diabetes. Design, setting, participants, & measurements: We studied 1441 participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Albumin excretion rate (AER) was quantified annually or biennially for up to 30 years. For each participant, albuminuria status was defined over time as normoalbuminuria (AER continuously 2 on two consecutive visits), and subclinical cardiovascular disease. Results: At least one cardiovascular event occurred in 184 participants, and 98 participants developed reduced eGFR. Compared with normoalbuminuria, sustained microalbuminuria, remitted microalbuminuria, and macroalbuminuria were each associated with higher risk of cardiovascular events (adjusted hazard ratios [HRs] and 95% confidence intervals [95% CIs]: 1.79 [1.13 to 2.85], 2.62 [1.68 to 4.07], and 2.65 [1.68 to 4.19], respectively) and reduced eGFR (adjusted HRs [95% CIs], 5.26 [2.43 to 11.41], 4.36 [1.80 to 10.57], and 54.35 [30.79 to 95.94], respectively). Compared with sustained microalbuminuria, remission to normoalbuminuria was not associated with reduced risk of cardiovascular events (adjusted HR, 1.33; 95% CI, 0.68 to 2.59) or reduced eGFR (adjusted HR, 1.75; 95% CI, 0.56 to 5.49). Compared with normoalbuminuria, sustained microalbuminuria, remitted microalbuminuria, and macroalbuminuria were associated with greater carotid intima-media thickness, and macroalbuminuria was associated with a greater degree of coronary artery calcification. Conclusions: In type 1 diabetes, microalbuminuria and macroalbuminuria are associated with higher risks of cardiovascular disease and reduced eGFR, but achieving a remission of established microalbuminuria to normoalbuminuria does not appear to improve outcomes.Keywords
This publication has 26 references indexed in Scilit:
- Drug-Induced Reduction in Albuminuria Is Associated with Subsequent RenoprotectionJournal of the American Society of Nephrology, 2015
- Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKDClinical Journal of the American Society of Nephrology, 2015
- Kidney Disease and Increased Mortality Risk in Type 2 DiabetesJournal of the American Society of Nephrology, 2013
- Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular DiseaseJournal of the American Society of Nephrology, 2011
- Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and MicroalbuminuriaAn Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications CohortMicroalbuminuria Outcomes in Type 1 DiabetesArchives of internal medicine (1960), 2011
- In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications StudyDiabetologia, 2010
- A New Equation to Estimate Glomerular Filtration RateAnnals of Internal Medicine, 2009
- The Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) StudyDiabetes, 2006
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesNew England Journal of Medicine, 2005
- Hemoglobin A1c Measurements over Nearly Two Decades: Sustaining Comparable Values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications StudyClinical Chemistry, 2005